Navigation Links
Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
Date:4/12/2011

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA.  The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011.  Jim Scopa from MPM will join the Conatus Board of Directors.

Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.

"We've watched the progress at Conatus and believe that CTS-1027 could make a significant difference in the treatment of HCV infection.  MPM also expects to provide other resources, both strategic and clinical, to assist the management team in the execution of its business plan", said Jim Scopa, Managing Director of MPM Capital.

"The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010," said Steven J. Mento, Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
2. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
3. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
10. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
11. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , Sept. 23, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... or the FDA, approved its request for Fast ... the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... -- Vesselon, Inc. today announced the appointment of Jurgen Raths, ... 2014. Dr. Raths, appointment follows Vesselon,s engagement with Spencer ... a private preferred Series A round to facilitate development ... "Jurgen,s deep experience across multiple functional areas of medical ... as we develop our device that can be compared ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
(Date:9/23/2014)... understanding of how living things function comes from knowledge ... of life, the receptors that are docking stations for ... and RNA that carry genetic blueprints for building cellular ... access to these structural details, a new grant just ... the U.S. Department of Energy (DOE) will fund the ...
(Date:9/23/2014)... New York, N.Y. (PRWEB) September 23, 2014 ... supplement to join the Royal Sport LTD family of ... 100 calories and 20g of pure Whey protein without ... , This ‘Ultra Clean’ protein is available on shelves ... Royal Sport LTD website—where the brand is offering a ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ADOMANI, Inc. ... serving as President and CEO. He is a 13-year veteran ... former President and CEO of A-Z Bus Sales of Colton, ... of their success, growing their top line revenues, profit and ... their gas or diesel to all-electric or plug-in hybrid ...
(Date:9/23/2014)... 2014 Airbus Helicopters Inc. (AHI) is ... as the 2014 Vision Zero Aviation Safety Award ... database, a free flight safety service the company provides ... - Air Medical Specialist for Airbus Helicopters Inc., presented ... check during the Air Medical Transport Conference Annual Community ...
(Date:9/23/2014)... special issue of the European Journal of Cancer ... research presented during the 1st EORTC Cancer Survivorship Summit ... diagnosis, targeted therapeutics, and more personalized multimodal treatments has ... to a large and rapidly increasing number of cancer ... confronted with a broad spectrum of late adverse treatment ...
Breaking Medicine News(10 mins):Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4
... a significantly enhanced quality of life in old age ... less afraid of death than their less religious peers ... professor of sociology at the University of New Hampshire. ... her collaborator, Paul Wink, professor of psychology at Wellesley ...
... for chronic obstructive pulmonary disease (COPD), can be ... new study. The research, presented at CHEST 2006 ... of the American College of Chest Physicians (ACCP), ... a large proportion of subjects with significant impairment. ...
... years will soon be assessed by a new random-dot stereotest ... article published in the November 2006 // issue of Investigative ... children, 38 with various visual impairments and 18 with normal ... alone with their heads stabilized by a chin and front ...
... law which makes possession of child pornography material a federal ... is a pedophile or become one based on the child ... number of cases are going to court and attorneys are ... person has child porn on their computer," said Dr. Humberto ...
... diabetes in middle age could face more complications later in ... new study.// ,Elizabeth Selvin of the Johns Hopkins Bloomberg ... than 2,800 people aged 65 and above with diabetes who ... the online edition of health Magazine WebMD. ,The ...
... Researchers from the Autonomous University of Tamaulipas are putting teeth ... of pacifiers by babies in their first year of birth, ... alignment in complete disarray. ,Researchers are armed to ... children between the ages of 4 and 5 who were ...
Cached Medicine News:Health News:Religious Adults Have a Higher Quality of Life than Their Peers 2Health News:Large Community Spirometry Screening Proves Successful 2Health News:Does Child pornography lead to Child abuse? 2Health News:Does Child pornography lead to Child abuse? 3
... Built-in 15 mm ISO termination for ... inner cannula in place. , ,Clearly ... inner cannula system , ,The Portex® ... constructed of siliconized polyvinyl chloride, providing a ...
... 15 mm ISO termination for easy ventilator ... in place., ,D.I.C.® tubes are available ... fenestrated styles. A color-coded system allows quick ... inner cannula. , ,The Portex® line ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Tube, tracheostomy, cuffed, size 8.0, SS, spiral reinforced PVC....
Medicine Products: